Ecology and control of infectious disease in vampire bats November,2 - 2016 - Peru

Photo: Marilene Almeida

Marilene Fernandes de Almeida

MSc, Ph.D. School of Medicine-University of São Paulo, Brazil. Laboratory of rabies - Zoonosis Control Center of São Paulo Municipality, Brazil.



Indirect immunization of *Desmodus rotundus* bat in captivity, with anti-rabies V-RG vaccine.







"Guano" is the base of food chain in the caves (detritivora chain), which permit the survive of one high number of parasitic species. (Aguiar & Taddei, 1996).

Numerous invertebrates live in and over the semi-liquid feces (Winsatt, 1970).

Properties of the VBSP-Vampire Bat Salivary Plasminogen activator - antithrombotic therapy (Gardell et al, 1990; Mellott et al., 1992, Witt et. Al, 1992).

The anticoagulant properties of the saliva was shown to increase blood flow in stroke patients. (January 10, 2003, J. the American Heart Association).



These observations suggested that any substance could be applied on the back of one bat, would be ingest by the vampire bat and the substance could be spread among the colony



Why not one vaccine?



























Rabies virus variant: brldr2918, isolated from *Desmodus rotundus* naturally infected.

Rabies Diagnostic: FAT Fluorescent antibody Mouse InoculationTest RT-PCR

Sequencing at Center for Diseases Control and Prevention - CDC Atlanta



		Res	ults		
	Rabies experim	ental infectio	n of Desmodus ro	tundus bat	
MICLD50	mortality (%)	bat	incubation period (days)	symptoms	morbidity (hours)
100	0				
1 000	20	A2	19		?
1,000	20	B2	41		?
10,000		H7	29	- +	24
10,000	20	20 Y7 32	32		
	60	Q12	5	- +	48
		X12	5		
100.000		Z12	5		
100,000		K12	9		24
		R12	9		
		F12	14		18
		X3	6		
		S3	5	- - - - - -	24
		F3	5		
		V3	5		
1.000,000	69.2	Y3	5		
		P4	5		
		S4	5		
		W4	5		
		C4	7		
control	0			-	

Experimental infection of *Desmodus rotundus* rabies virus according diagnostic test

FA,	MIT / RT-PCR	FA MIT/F	RT-PCR
	brain	salivar glands	\$
Infected	+	4	6
control	-	-	-
survivor	-	-	-

CLINICAL ASPECTS

All animals that developed rabies showed signs of paralytic rabies: weakness, muscular tremors, muscular spasms, impossibility to stand on their feet and thumbs, lack of coordination of posterior limbs, irritability to light, wind and sounds, paralysis and prostration.

None clinical manifestation associated with furious rabies was observed in the sick animals.





EXPERIMENTAL INFECTION Serology - - Results Serum samples were seronegative to VNA before the experiment. 97.2% of the bats showed increase in the level of antibodies on day 30. VNA titres above 0.5IU/mL were found in 52.7% of bats on day 30, 43.7% on day 60 and 34.5% on day 90 after inoculation.

EXPERIMENTAL INFECTION Serology - Results

It was observed resistance to experimental infection in animals with low titres of antibodies (<0,5IU/mL) in all groups, independently of the dose inoculated.

Animals that received the highest inoculums developed the highest antibodies titres. (p=0.0002).

EXPERIMENTAL INFECTION Conclusions

Bats were able to survive a large dose of rabies virus and produced antibody titers that would be considered "protective" in humans

IMUNOGENICITY OF VACCINE AND ORAL ROUTE





Vaccine: Raboral V-RG - Merial

Recombinant: A life-modified Vaccinia Virus (Copenhagen strain) express the rabies glycoprotein (ERA strain).

Potency: 10⁸ e 10⁹.

A sachet containing rabies vaccine is inserted into the baits and sealed in with wax.









Oral route - Serology

The majority (94.7%) showed increase of titers 20 days after vaccination, but VNA titers above 0.5IU/ml were found only in 26.3% of bats.

After the challenge, 92.1% of the animals showed titers above 0.5IU/ml and 80% of the survivors showed titers above 0.5IU/ml on day 90 (0.6 to 3.2IU/ml).

Animals with low titres of antibodies resist to challenge after vaccination.











SURVIVAL	AFTER	VACCINATION	AND
	CHAL	LENGE	

Dose	Number	Incubation	Morbidity	SURVIVAL
Vaccine	of bats	Period (days)	Period (hours)	%
Nine (A)	7	6 to 15	18 to 24	42,8
Nine (B)	7	7 to 11	18 to 24	71,4
Nine (C)	7	5 to 9	24 to 48	57,1
Nine (D)	7	5	24 to 48	57,1
Nine (E)	7	5 to 6	24	71,4
Eighteen (F)	8	5	48	62,5
Eighteen (G)	9	5 to 10	24 to 48	55,5
Eighteen (H)	10	5 to 11	18 to 24	60



	Serology		
	mouth/dialysis	paste/dialysis	
after vaccination	94.7%	71.7%	
0.5IU/ml	26.3%	20%	
after challenge	92.1%	79.3%	
sacrifice	80%	57.1%	
SURVIVAL	100%	71.4%	



ALL ANIMALS SHOWED SIGNS OF CONTACT WITH THE MIX (VACCINE/PASTE/COLOR)

This contact can't be determined numerically, just estimated through survival after challenge.









VACCINE PASTE ROUTE

ULTRAFILTRATION

Other method to concentrate the vaccine in order to obtain one mix (paste + vaccine + color) with the adequate consistency.





Ultrafiltration by cellulose membrane with porous of 50.000 Daltons



SURVIVAL AFTER VACCINATION BY PASTE AND CHALLENGE

Ultrafiltration

Survival proportion 71.4% (Groups 9 and 12) 100% (Group 10) (9 sachets of vaccine - 0.8ml final volume - 7 bats)

Dyalisis Survival proportion - 71.4% (Groups B and E) (9 sachets - 1.2/1.5ml final volume - 7 bats)



	Corology	,
	Servicy	
	paste/dialysis %	paste/ultrafiltration %
after vaccination	71.7	84.2
0.5IU/ml	20	63.1
after challenge	79.3	93.3
sacrifice	57.1	100

The method to vaccine concentration by ultrafiltration improved the prior results in the serology